UNSPSC 51320000: Antihyperlipidemic and hypocholesterolemic agents

This classification denotes substances that lower the levels of certain lipids in the blood.

UNSPSC 51320000 Antihyperlipidemic and hypocholesterolemic agents (Family) covers pharmaceutical products purchased by state and local health agencies, emergency services, and cooperative purchasing alliances to stock emergency medicine cabinets, pharmacy benefit programs, and multi-state distribution networks. Recent solicitations show that state and local buyers under this code are acquiring generic pharmaceuticals and over-the-counter products through both direct procurement and cooperative purchasing arrangements, with a focus on cost-competitive pricing, supply-chain compliance (cGMP, DSCSA), and standardized product specifications tied to National Drug Codes. Issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The Tampa and MMCAP solicitations show preference for vendors who can manage expiration-date compliance, establish relationships with authorized wholesalers, and absorb freight and logistics costs.

Activity spans Florida, Texas, Minnesota, and Oregon, with MMCAP representing a particularly active multi-jurisdictional buying vehicle. Representative recent solicitations include the City of Tampa's sealed-bid procurement (IFB No. 26P00188, due April 8, 2026) for Advanced Life Support Medications totaling approximately $40,000 for Tampa Fire Rescue, requiring supply of Labetalol, Epinephrine, Adenosine, and Diltiazem with nine-month minimum shelf life and one-year contract terms with renewal options; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and requirements for cGMP certification, DSCSA compliance, and $5 million commercial general liability insurance. The Texas HHS Commission also posted an RFI (HHS0017013, April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels, signaling emerging interest in alternative supply pathways for state pharmacy benefit programs.